CONTINUITY BIOSCIENCES, LLC
SBIR Phase II award from Department of Health and Human Services.
Summary
Continuity Biosciences, LLC received nearly $3 million from NIH for a Direct-to-Phase II SBIR award to develop a novel iontophoretic device that delivers drugs locally to treat oral cancer. The project focuses on creating an effective, targeted treatment option using electric current for drug delivery.
- Amount
- $2,995,581
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- NC
- Period
- 2025-09-05 → 2027-09-04
Technology domains
Human Performance & Medical
Description
DIRECT TO PHASE II SBIR CONCEPT AWARD FOR NOVEL IONTOPHORETIC DRUG DELIVERY DEVICE FOR LOCAL AND EFFECTIVE TREATMENT OF ORAL CANCER